Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
This is a poorly constructed and dangerous article. Its incorrect assertion regarding the imminent demise of the coronavirus when vaccines are introduced is irresponsible. This might encourage individuals, who have already disregarded COVID protocols to intensify their selfish lifestyles and put more people in danger.
Further, I wish that the negative and semi-illiterate commentators, who only appear when a share price is in decline would go away. I see no rationale for their comments other than that they may be short-term sellers or paid stooges of institutions, who have a financial interest in the continued decline of the share price. I have already filtered “robsaunders”,and “Shemar” for that reason. “Motherf****r” has just been added to the list.
I tho k this article is positive coverage in the readership we want to see. It says we are oversold at 40% drop, says IF covid goes away, mentions other uses and kindly slips on 11 times upside from the broker. Many people will spot those facts amongst the vaccine stuff and good publicity for investors who haven’t heard of us.
Let’s see if it helps to SP today/tomorrow
Yes Bella but that is what the market is currently missing and providing an opportunity here to buy at level I never thought we would see again. Over the weeks and months people will realise that this fact of 'total vaccination' will not happen, there will be stories in the media of people being vaccinated but then catching covid and the market will eventually wake up to the need of long term treatments needing to be available as covid still exists in the world's population. Maybe not at the levels that it does now but this is now endemic. All IMO of course.
'if we are all going to be vaccinated against the virus over the next few months,'
This is a blatantly incorrect statement and totally irresponsible statement...
If we are using interferon produced in US to facilitate manufacturing in US will we seriously be looking to ship and sell everything only to the UK???
Guys I am not agreeing with that article because I too think it is irrational. I am simply saying that is the way it comes across, they are trying to be positive but not really if you get what I mean.
It is positive. Let’s be happy with that!
And no one is pricing in the sale of our product which will be rolling off the line in 2021 if not already. Once someone decides it’s sensible to stockpile a few and we get hundreds of £millions or even £billions rolling in, we’ll be kicking ourselves for not topping up at these prices. Mr Market gets it wrong frequently.
“It is easy to see investors’ logic: if we are all going to be vaccinated against the virus over the next few months”
Pretty illogical if you ask me!
Agree mike29. However, the news on Convalescent Plasma is definitely a significant win for SNG001 as it has knocked a potential competitor into touch.
To me it is a small positive and that’s it. The things in there I don’t like is, they are more or less agreeing that our use for covid is all but gone and it’s back to Copd. Also the target of 9.90 is pie in the sky now. That’s the way I read it, but thankful for small mercies I guess.
Yes it is a tip for SNG. Here is the article:
‘The advent of three viable coronavirus vaccines is great news – unless, like London-quoted Synairgen, you make treatments for the disease.
On Nov 9, when the success of the Pfizer/ BioNTech vaccine was announced, shares in the firm fell by 39pc. They had jumped more than fivefold on July 20, when the success of its own treatment for Covid-19 in hospital trials was reported.
It is easy to see investors’ logic: if we are all going to be vaccinated against the virus over the next few months, there will be far fewer people admitted to hospital with the disease and much less need for treatments.
That may be true. But the success against coronavirus of Synairgen’s treatment, a drug called interferon beta in a form delivered directly to the lungs, suggests that it could be effective against other respiratory diseases that we cannot expect to disappear in the next year or so.
This at least is the view of one fund manager Questor spoke to and also of analysts at Numis, the broker.
Now stockbrokers’ analysts can get carried away so perhaps we should take Numis’s share price target of 990p – more than 11 times the current price – with a pinch of salt. But the stock, which is quoted on Aim, may be worth a flutter with a small slice of your Isa or pension.’
Oops missed the last para:
Now stockbrokers’ analysts can get carried away so perhaps we should take Numis’s share price target of 990p – more than 11 times the current price – with a pinch of salt. But the stock, which is quoted on Aim, may be worth a flutter with a small slice of your Isa or pension.
The advent of three viable coronavirus vaccines is great news – unless, like London-quoted Synairgen, you make treatments for the disease.
On Nov 9, when the success of the Pfizer/ BioNTech vaccine was announced, shares in the firm fell by 39pc. They had jumped more than fivefold on July 20, when the success of its own treatment for Covid-19 in hospital trials was reported.
It is easy to see investors’ logic: if we are all going to be vaccinated against the virus over the next few months, there will be far fewer people admitted to hospital with the disease and much less need for treatments.
That may be true. But the success against coronavirus of Synairgen’s treatment, a drug called interferon beta in a form delivered directly to the lungs, suggests that it could be effective against other respiratory diseases that we cannot expect to disappear in the next year or so.
This at least is the view of one fund manager Questor spoke to and also of analysts at Numis, the broker.
I don’t subscribe but your link takes me straight past the paywall.
Sorry I don’t have access to this but seems like it’s a positive spin suggesting SNG has been oversold...
https://www.telegraph.co.uk/investing/shares/questor-two-stocks-knocked-back-vaccines-one-set-fair-worth/